Overview:

This CE session will focus on optimizing type 2 diabetes care with guideline-recommended GLP-1 RA and dual GIP/GLP-1 RA therapies. The program includes a concise update from a diabetes expert pharmacist and interactive case-based breakouts tackling real-world challenges in care. Attendees will gain practical strategies to overcome barriers, improve cardiometabolic outcomes, and support patient access. At the conclusion of the session, attendees will receive a QR code linking to a train-the-trainer toolkit (slides with speaker notes, cases with discussion guides, and facilitator notes) to support delivering the program to their own teams. The QR code will also provide a PDF summarizing targeted “Actions to Take Now” to address gaps in clinical practice, along with best practices, FAQs, and implementation insights to support real-world application. 

Educational Objectives

•    Apply knowledge of the clinical and economic burden of type 2 diabetes (T2D) and its associated complications to inform patient care decisions and advocate for timely glycemic control. 

•    Explore evidence-based recommendations for the integration of approved and emerging incretin-based therapies in diabetes management plans.

•    Analyze the evidence for cardiorenal-metabolic benefits of guideline-recommended treatments for T2D.

•    Implement pharmacist-driven strategies to prevent therapeutic inertia in diabetes management.

Speaker:

This activity is supported by an educational grant from Lilly.

Activity Disclaimer